{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T21:15:16Z","timestamp":1790716516036,"version":"4.1.0"},"reference-count":168,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81160294"],"award-info":[{"award-number":["81160294"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81960425"],"award-info":[{"award-number":["81960425"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Experimental Cell Research"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.yexcr.2026.115154","type":"journal-article","created":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T14:59:52Z","timestamp":1786633192000},"page":"115154","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Targeting the ubiquitin-proteasome system: An emerging paradigm for overcoming resistance to targeted therapy in non-small cell lung cancer"],"prefix":"10.1016","volume":"462","author":[{"given":"Rui","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kailang","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junping","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.yexcr.2026.115154_bib1","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2020.103194","article-title":"Molecular testing and targeted therapy for non-small cell lung cancer: current status and perspectives","volume":"157","author":"Imyanitov","year":"2021","journal-title":"Crit. Rev. Oncol. Hematol."},{"issue":"3","key":"10.1016\/j.yexcr.2026.115154_bib2","doi-asserted-by":"crossref","DOI":"10.3390\/curroncol32030146","article-title":"Lung cancer: targeted therapy in 2025","volume":"32","author":"Bouchard","year":"2025","journal-title":"Curr. Oncol."},{"issue":"23","key":"10.1016\/j.yexcr.2026.115154_bib3","doi-asserted-by":"crossref","DOI":"10.3390\/ijms232315056","article-title":"Non-small cell lung cancer targeted therapy: drugs and mechanisms of drug resistance","volume":"23","author":"Wu","year":"2022","journal-title":"Int. J. Mol. Sci."},{"issue":"3","key":"10.1016\/j.yexcr.2026.115154_bib4","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1039\/D2MO00261B","article-title":"Lnc-TMEM132D-AS1 as a potential therapeutic target for acquired resistance to osimertinib in non-small-cell lung cancer","volume":"19","author":"Wang","year":"2023","journal-title":"Mol Omics"},{"key":"10.1016\/j.yexcr.2026.115154_bib5","doi-asserted-by":"crossref","DOI":"10.1016\/j.biocel.2022.106344","article-title":"CircSETD3 mediates acquired resistance to gefitinib in non-small lung cancer cells by FXR1\/ECT2 pathway","volume":"154","author":"Wen","year":"2023","journal-title":"Int. J. Biochem. Cell Biol."},{"issue":"9","key":"10.1016\/j.yexcr.2026.115154_bib6","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1517\/14728222.2013.815728","article-title":"Targeting the ubiquitin-proteasome system for cancer therapy","volume":"17","author":"Shen","year":"2013","journal-title":"Expert Opin. Ther. Targets"},{"issue":"8","key":"10.1016\/j.yexcr.2026.115154_bib7","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1593\/neo.06376","article-title":"E3 ubiquitin ligases as cancer targets and biomarkers","volume":"8","author":"Sun","year":"2006","journal-title":"Neoplasia"},{"issue":"20","key":"10.1016\/j.yexcr.2026.115154_bib8","doi-asserted-by":"crossref","DOI":"10.3390\/ijms252011214","article-title":"Proteolysis targeting chimera agents (PROTACs): new hope for overcoming the resistance mechanisms in oncogene-addicted non-small cell lung cancer","volume":"25","author":"Cordani","year":"2024","journal-title":"Int. J. Mol. Sci."},{"issue":"7","key":"10.1016\/j.yexcr.2026.115154_bib9","doi-asserted-by":"crossref","DOI":"10.1111\/cpr.70050","article-title":"Mechanistic insights and therapeutic potentials of ubiquitin-proteasome system in non-small cell lung cancer","volume":"58","author":"Zhou","year":"2025","journal-title":"Cell Prolif."},{"key":"10.1016\/j.yexcr.2026.115154_bib10","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1146\/annurev-biochem-060815-014922","article-title":"Ubiquitin ligases: structure, function, and regulation","volume":"86","author":"Zheng","year":"2017","journal-title":"Annu. Rev. Biochem."},{"issue":"2","key":"10.1016\/j.yexcr.2026.115154_bib11","doi-asserted-by":"crossref","first-page":"157","DOI":"10.2174\/1568009616666151112122801","article-title":"RING-, HECT-, and RBR-type E3 ubiquitin ligases: involvement in human cancer","volume":"16","author":"Uchida","year":"2016","journal-title":"Curr. Cancer Drug Targets"},{"issue":"1","key":"10.1016\/j.yexcr.2026.115154_bib12","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s11658-020-00245-6","article-title":"Beyond K48 and K63: non-canonical protein ubiquitination","volume":"26","author":"Tracz","year":"2021","journal-title":"Cell. Mol. Biol. Lett."},{"issue":"2","key":"10.1016\/j.yexcr.2026.115154_bib13","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1038\/s41594-024-01221-w","article-title":"Breaking the K48-chain: linking ubiquitin beyond protein degradation","volume":"31","author":"Rahman","year":"2024","journal-title":"Nat. Struct. Mol. Biol."},{"issue":"1","key":"10.1016\/j.yexcr.2026.115154_bib14","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1038\/s41420-022-01204-0","article-title":"Role of K63-linked ubiquitination in cancer","volume":"8","author":"Cao","year":"2022","journal-title":"Cell Death Discov."},{"key":"10.1016\/j.yexcr.2026.115154_bib15","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1146\/annurev-biochem-062917-011931","article-title":"Structure and function of the 26S proteasome","volume":"87","author":"Bard","year":"2018","journal-title":"Annu. Rev. Biochem."},{"issue":"6","key":"10.1016\/j.yexcr.2026.115154_bib16","doi-asserted-by":"crossref","DOI":"10.1152\/ajpcell.00553.2024","article-title":"Deubiquitinases in skeletal muscle-the underappreciated side of the ubiquitination coin","volume":"327","author":"Du","year":"2024","journal-title":"Am. J. Physiol. Cell Physiol."},{"issue":"1","key":"10.1016\/j.yexcr.2026.115154_bib17","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1186\/s12943-024-02046-3","article-title":"Ubiquitination and deubiquitination in cancer: from mechanisms to novel therapeutic approaches","volume":"23","author":"Liu","year":"2024","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.yexcr.2026.115154_bib18","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.biocel.2018.06.001","article-title":"Ubiquitination: friend and foe in cancer","volume":"101","author":"Mansour","year":"2018","journal-title":"Int. J. Biochem. Cell Biol."},{"issue":"17","key":"10.1016\/j.yexcr.2026.115154_bib19","doi-asserted-by":"crossref","first-page":"4984","DOI":"10.1158\/0008-5472.CAN-17-3858","article-title":"Upregulation of E3 ubiquitin ligase CBLC enhances EGFR dysregulation and signaling in lung adenocarcinoma","volume":"78","author":"Hong","year":"2018","journal-title":"Cancer Res."},{"issue":"6877","key":"10.1016\/j.yexcr.2026.115154_bib20","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1038\/416183a","article-title":"Cbl-CIN85-endophilin complex mediates ligand-induced downregulation of EGF receptors","volume":"416","author":"Soubeyran","year":"2002","journal-title":"Nature"},{"issue":"5","key":"10.1016\/j.yexcr.2026.115154_bib21","doi-asserted-by":"crossref","first-page":"498","DOI":"10.3390\/cells8050498","article-title":"c-Cbl: an important regulator and a target in angiogenesis and tumorigenesis","volume":"8","author":"Lyle","year":"2019","journal-title":"Cells"},{"key":"10.1016\/j.yexcr.2026.115154_bib22","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.cellsig.2017.11.006","article-title":"Phosphorylation of Mig6 negatively regulates the ubiquitination and degradation of EGFR mutants in lung adenocarcinoma cell lines","volume":"43","author":"Boopathy","year":"2018","journal-title":"Cell. Signal."},{"issue":"10","key":"10.1016\/j.yexcr.2026.115154_bib23","doi-asserted-by":"crossref","first-page":"2579","DOI":"10.1002\/ijc.33404","article-title":"Targeting USP13-mediated drug tolerance increases the efficacy of EGFR inhibition of mutant EGFR in non-small cell lung cancer","volume":"148","author":"Giron","year":"2021","journal-title":"Int. J. Cancer"},{"issue":"14","key":"10.1016\/j.yexcr.2026.115154_bib24","doi-asserted-by":"crossref","first-page":"3894","DOI":"10.1158\/1078-0432.CCR-12-3696","article-title":"USP8 is a novel target for overcoming gefitinib resistance in lung cancer","volume":"19","author":"Byun","year":"2013","journal-title":"Clin. Cancer Res."},{"issue":"40","key":"10.1016\/j.yexcr.2026.115154_bib25","doi-asserted-by":"crossref","first-page":"5387","DOI":"10.1038\/s41388-018-0342-9","article-title":"Stratifin regulates stabilization of receptor tyrosine kinases via interaction with ubiquitin-specific protease 8 in lung adenocarcinoma","volume":"37","author":"Kim","year":"2018","journal-title":"Oncogene"},{"issue":"1","key":"10.1016\/j.yexcr.2026.115154_bib26","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1186\/s40364-025-00806-x","article-title":"USP21-EGFR-Lyn axis drives NSCLC progression and therapeutic potential of USP21 inhibition","volume":"13","author":"Shin","year":"2025","journal-title":"Biomark. Res."},{"issue":"4","key":"10.1016\/j.yexcr.2026.115154_bib27","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0320668","article-title":"Deubiquitination of epidermal growth factor receptor by ubiquitin-specific peptidase 54 enhances drug sensitivity to gefitinib in gefitinib-resistant non-small cell lung cancer cells","volume":"20","author":"Kim","year":"2025","journal-title":"PLoS One"},{"issue":"13","key":"10.1016\/j.yexcr.2026.115154_bib28","doi-asserted-by":"crossref","first-page":"1660","DOI":"10.1038\/onc.2012.188","article-title":"The ubiquitin-specific protease USP2a prevents endocytosis-mediated EGFR degradation","volume":"32","author":"Liu","year":"2013","journal-title":"Oncogene"},{"key":"10.1016\/j.yexcr.2026.115154_bib29","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.canlet.2018.07.002","article-title":"USP22 promotes resistance to EGFR-TKIs by preventing ubiquitination-mediated EGFR degradation in EGFR-mutant lung adenocarcinoma","volume":"433","author":"Zhang","year":"2018","journal-title":"Cancer Lett."},{"issue":"1","key":"10.1016\/j.yexcr.2026.115154_bib30","doi-asserted-by":"crossref","first-page":"3660","DOI":"10.1038\/s41467-020-17385-0","article-title":"TRIB3-EGFR interaction promotes lung cancer progression and defines a therapeutic target","volume":"11","author":"Yu","year":"2020","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.yexcr.2026.115154_bib31","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1186\/s13046-023-02692-3","article-title":"Kremen2 drives the progression of non-small cell lung cancer by preventing SOCS3-mediated degradation of EGFR","volume":"42","author":"Sun","year":"2023","journal-title":"J. Exp. Clin. Cancer Res."},{"issue":"10","key":"10.1016\/j.yexcr.2026.115154_bib32","doi-asserted-by":"crossref","DOI":"10.3390\/ijms24108794","article-title":"JAC4 inhibits EGFR-driven lung adenocarcinoma growth and metastasis through CTBP1-Mediated JWA\/AMPK\/NEDD4L\/EGFR axis","volume":"24","author":"Ding","year":"2023","journal-title":"Int. J. Mol. Sci."},{"issue":"2","key":"10.1016\/j.yexcr.2026.115154_bib33","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1007\/s13402-022-00669-6","article-title":"FBXO32 targets PHPT1 for ubiquitination to regulate the growth of EGFR mutant lung cancer","volume":"45","author":"Zhang","year":"2022","journal-title":"Cell. Oncol."},{"issue":"7","key":"10.1016\/j.yexcr.2026.115154_bib34","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbc.2025.110305","article-title":"Calcium triggers calmodulin degradation to induce EGF receptor instability and overcome non-small cell lung cancer resistance to tyrosine kinase inhibitors","volume":"301","author":"Li","year":"2025","journal-title":"J. Biol. Chem."},{"issue":"47","key":"10.1016\/j.yexcr.2026.115154_bib35","doi-asserted-by":"crossref","first-page":"6180","DOI":"10.1038\/s41388-018-0397-7","article-title":"Bruton's tyrosine kinase potentiates ALK signaling and serves as a potential therapeutic target of neuroblastoma","volume":"37","author":"Li","year":"2018","journal-title":"Oncogene"},{"issue":"11","key":"10.1016\/j.yexcr.2026.115154_bib36","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2024.114917","article-title":"USP7 deubiquitinates KRAS and promotes non-small cell lung cancer","volume":"43","author":"Huang","year":"2024","journal-title":"Cell Rep."},{"issue":"7","key":"10.1016\/j.yexcr.2026.115154_bib37","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1158\/1541-7786.MCR-16-0369","article-title":"Deubiquitinase USP18 loss mislocalizes and destabilizes KRAS in lung cancer","volume":"15","author":"Mustachio","year":"2017","journal-title":"Mol. Cancer Res."},{"issue":"1","key":"10.1016\/j.yexcr.2026.115154_bib38","doi-asserted-by":"crossref","first-page":"2572","DOI":"10.1038\/s41467-022-30149-2","article-title":"AIMP2-DX2 provides therapeutic interface to control KRAS-driven tumorigenesis","volume":"13","author":"Kim","year":"2022","journal-title":"Nat. Commun."},{"issue":"3","key":"10.1016\/j.yexcr.2026.115154_bib39","doi-asserted-by":"crossref","first-page":"288","DOI":"10.15252\/emmm.201505972","article-title":"OTUB1 triggers lung cancer development by inhibiting RAS monoubiquitination","volume":"8","author":"Baietti","year":"2016","journal-title":"EMBO Mol. Med."},{"key":"10.1016\/j.yexcr.2026.115154_bib40","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2025.107722","article-title":"Targeting USP47 enhances the efficacy of KRAS inhibitor in KRAS(G12C) mutated non-small cell lung cancer by controlling deubiquitination of c-Myc","volume":"215","author":"Shin","year":"2025","journal-title":"Pharmacol. Res."},{"issue":"12","key":"10.1016\/j.yexcr.2026.115154_bib41","doi-asserted-by":"crossref","DOI":"10.1016\/j.devcel.2025.01.015","article-title":"KRAS4B oncogenic mutants promote non-small cell lung cancer progression via the interaction of deubiquitinase USP25 with RNF31","volume":"60","author":"Yang","year":"2025","journal-title":"Dev. Cell"},{"key":"10.1016\/j.yexcr.2026.115154_bib42","doi-asserted-by":"crossref","DOI":"10.1177\/15230864251377765","article-title":"Empagliflozin attenuates diabetic cardiomyopathy via inhibiting cardiomyocyte ferroptosis through the USP7\/NRF2 signaling pathway","author":"Cui","year":"2025","journal-title":"Antioxid Redox Signal"},{"issue":"7677","key":"10.1016\/j.yexcr.2026.115154_bib43","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1038\/nature24451","article-title":"Molecular basis of USP7 inhibition by selective small-molecule inhibitors","volume":"550","author":"Turnbull","year":"2017","journal-title":"Nature"},{"issue":"5827","key":"10.1016\/j.yexcr.2026.115154_bib44","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1126\/science.1141478","article-title":"MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling","volume":"316","author":"Engelman","year":"2007","journal-title":"Science"},{"issue":"1","key":"10.1016\/j.yexcr.2026.115154_bib45","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1097\/JTO.0b013e3181913e0e","article-title":"Activation of MET by gene amplification or by splice mutations deleting the juxtamembrane domain in primary resected lung cancers","volume":"4","author":"Onozato","year":"2009","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.yexcr.2026.115154_bib46","doi-asserted-by":"crossref","DOI":"10.1155\/2022\/5687832","article-title":"Licochalcone A promotes the ubiquitination of c-Met to abrogate gefitinib resistance","volume":"2022","author":"Han","year":"2022","journal-title":"Biomed Res. Int."},{"issue":"1","key":"10.1016\/j.yexcr.2026.115154_bib47","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1038\/s41420-024-02220-y","article-title":"Xanthohumol overcomes osimertinib resistance via governing ubiquitination-modulated Ets-1 turnover","volume":"10","author":"Ma","year":"2024","journal-title":"Cell Death Discov."},{"issue":"6","key":"10.1016\/j.yexcr.2026.115154_bib48","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.186165","article-title":"Piperlongumine overcomes osimertinib resistance via governing ubiquitination-modulated Sp1 turnover","volume":"10","author":"Wang","year":"2025","journal-title":"JCI Insight"},{"key":"10.1016\/j.yexcr.2026.115154_bib49","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2020.118316","article-title":"USP33 regulates c-Met expression by deubiquitinating SP1 to facilitate metastasis in hepatocellular carcinoma","volume":"261","author":"Gan","year":"2020","journal-title":"Life Sci."},{"issue":"10","key":"10.1016\/j.yexcr.2026.115154_bib50","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1038\/s41419-023-06201-4","article-title":"PTPN23 ubiquitination by WDR4 suppresses EGFR and c-MET degradation to define a lung cancer therapeutic target","volume":"14","author":"Singh","year":"2023","journal-title":"Cell Death Dis."},{"issue":"1","key":"10.1016\/j.yexcr.2026.115154_bib51","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1038\/s41420-022-01023-3","article-title":"ORP5 promotes tumor metastasis via stabilizing c-Met in renal cell carcinoma","volume":"8","author":"Song","year":"2022","journal-title":"Cell Death Discov."},{"key":"10.1016\/j.yexcr.2026.115154_bib52","doi-asserted-by":"crossref","DOI":"10.1016\/j.lungcan.2026.108939","article-title":"Targeting HGF\/MET and CXCL1\/CXCR2 axes bypasses resistance to KRAS(G12C) inhibitors in NSCLC","volume":"213","author":"Cavazzoni","year":"2026","journal-title":"Lung Cancer"},{"issue":"6","key":"10.1016\/j.yexcr.2026.115154_bib53","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1038\/s41401-024-01237-4","article-title":"Brigatinib, a newly discovered AXL inhibitor, suppresses AXL-mediated acquired resistance to osimertinib in EGFR-mutated non-small cell lung cancer","volume":"45","author":"Han","year":"2024","journal-title":"Acta Pharmacol. Sin."},{"issue":"1","key":"10.1016\/j.yexcr.2026.115154_bib54","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1186\/s12964-019-0377-8","article-title":"Targeting of the AXL receptor tyrosine kinase by small molecule inhibitor leads to AXL cell surface accumulation by impairing the ubiquitin-dependent receptor degradation","volume":"17","author":"Lauter","year":"2019","journal-title":"Cell Commun. Signal."},{"issue":"2","key":"10.1016\/j.yexcr.2026.115154_bib55","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1158\/1541-7786.MCR-18-0628","article-title":"Activation of AXL as a preclinical acquired resistance mechanism against osimertinib treatment in EGFR-mutant non-small cell lung cancer cells","volume":"17","author":"Namba","year":"2019","journal-title":"Mol. Cancer Res."},{"issue":"25","key":"10.1016\/j.yexcr.2026.115154_bib56","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2300310120","article-title":"WNK1 controls endosomal trafficking through TRIM27-dependent regulation of actin assembly","volume":"120","author":"Jung","year":"2023","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"8","key":"10.1016\/j.yexcr.2026.115154_bib57","doi-asserted-by":"crossref","first-page":"2240","DOI":"10.1158\/1078-0432.CCR-12-2246","article-title":"Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers","volume":"19","author":"Yu","year":"2013","journal-title":"Clin. Cancer Res."},{"issue":"6","key":"10.1016\/j.yexcr.2026.115154_bib58","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1007\/s13402-025-01107-z","article-title":"Pyrotinib inhibits the tumorigenicity of HER2-positive non-small cell lung cancer by inducing ARIH1\/ubiquitin\/lysosome-dependent degradation of HER2","volume":"48","author":"Li","year":"2025","journal-title":"Cell. Oncol."},{"issue":"2","key":"10.1016\/j.yexcr.2026.115154_bib59","doi-asserted-by":"crossref","first-page":"275","DOI":"10.2478\/v10039-011-0043-x","article-title":"Blocking the PI3K\/AKT and MEK\/ERK signaling pathways can overcome gefitinib-resistance in non-small cell lung cancer cell lines","volume":"56","author":"Li","year":"2011","journal-title":"Adv. Med. Sci."},{"issue":"21","key":"10.1016\/j.yexcr.2026.115154_bib60","doi-asserted-by":"crossref","first-page":"3989","DOI":"10.1038\/s41388-019-0713-x","article-title":"Control of mTOR signaling by ubiquitin","volume":"38","author":"Jiang","year":"2019","journal-title":"Oncogene"},{"key":"10.1016\/j.yexcr.2026.115154_bib61","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.mito.2016.03.007","article-title":"Mitochondrial E3 ubiquitin ligase 1: a key enzyme in regulation of mitochondrial dynamics and functions","volume":"28","author":"Peng","year":"2016","journal-title":"Mitochondrion"},{"issue":"3","key":"10.1016\/j.yexcr.2026.115154_bib62","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1016\/j.bbrc.2017.06.151","article-title":"NMR uncovers direct interaction between human NEDD4-1 and p34SEI-1","volume":"490","author":"Shrestha","year":"2017","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"25","key":"10.1016\/j.yexcr.2026.115154_bib63","doi-asserted-by":"crossref","first-page":"8585","DOI":"10.1073\/pnas.0803233105","article-title":"The ubiquitin ligase Nedd4-1 is dispensable for the regulation of PTEN stability and localization","volume":"105","author":"Fouladkou","year":"2008","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"11","key":"10.1016\/j.yexcr.2026.115154_bib64","doi-asserted-by":"crossref","first-page":"1814","DOI":"10.1038\/s12276-022-00887-w","article-title":"The equilibrium of tumor suppression: DUBs as active regulators of PTEN","volume":"54","author":"Christine","year":"2022","journal-title":"Exp. Mol. Med."},{"issue":"6441","key":"10.1016\/j.yexcr.2026.115154_bib65","doi-asserted-by":"crossref","DOI":"10.1126\/science.aau0159","article-title":"Reactivation of PTEN tumor suppressor for cancer treatment through inhibition of a MYC-WWP1 inhibitory pathway","volume":"364","author":"Lee","year":"2019","journal-title":"Science"},{"key":"10.1016\/j.yexcr.2026.115154_bib66","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.semcancer.2021.06.012","article-title":"The HECT family of E3 ubiquitin ligases and PTEN","volume":"85","author":"Song","year":"2022","journal-title":"Semin. Cancer Biol."},{"issue":"6","key":"10.1016\/j.yexcr.2026.115154_bib67","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1038\/ncb2240","article-title":"WWP2 is an E3 ubiquitin ligase for PTEN","volume":"13","author":"Maddika","year":"2011","journal-title":"Nat. Cell Biol."},{"issue":"4","key":"10.1016\/j.yexcr.2026.115154_bib68","doi-asserted-by":"crossref","DOI":"10.1016\/j.molcel.2022.01.002","article-title":"E3 ligase RNF167 and deubiquitinase STAMBPL1 modulate mTOR and cancer progression","volume":"82","author":"Wang","year":"2022","journal-title":"Mol. Cell"},{"issue":"6","key":"10.1016\/j.yexcr.2026.115154_bib69","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1128\/MCB.01389-12","article-title":"Ubiquitin hydrolase UCH-L1 destabilizes mTOR complex 1 by antagonizing DDB1-CUL4-mediated ubiquitination of raptor","volume":"33","author":"Hussain","year":"2013","journal-title":"Mol. Cell Biol."},{"issue":"5","key":"10.1016\/j.yexcr.2026.115154_bib70","doi-asserted-by":"crossref","DOI":"10.3892\/ijo.2021.5270","article-title":"Mechanisms and management of 3rd-generation EGFR-TKI resistance in advanced non-small cell lung cancer","volume":"59","author":"He","year":"2021","journal-title":"Int. J. Oncol."},{"issue":"1","key":"10.1016\/j.yexcr.2026.115154_bib71","doi-asserted-by":"crossref","first-page":"2551","DOI":"10.1038\/s41467-024-46521-3","article-title":"The EIF3H-HAX1 axis increases RAF-MEK-ERK signaling activity to promote colorectal cancer progression","volume":"15","author":"Jin","year":"2024","journal-title":"Nat. Commun."},{"issue":"9","key":"10.1016\/j.yexcr.2026.115154_bib72","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1038\/s41556-021-00732-8","article-title":"TRIM15 and CYLD regulate ERK activation via lysine-63-linked polyubiquitination","volume":"23","author":"Zhu","year":"2021","journal-title":"Nat. Cell Biol."},{"issue":"16","key":"10.1016\/j.yexcr.2026.115154_bib73","doi-asserted-by":"crossref","first-page":"3017","DOI":"10.1002\/1878-0261.13290","article-title":"Fbxo45-mediated NP-STEP(46) degradation via K6-linked ubiquitination sustains ERK activity in lung cancer","volume":"16","author":"Wang","year":"2022","journal-title":"Mol. Oncol."},{"issue":"14","key":"10.1016\/j.yexcr.2026.115154_bib74","doi-asserted-by":"crossref","first-page":"3982","DOI":"10.1158\/0008-5472.CAN-18-0429","article-title":"TRAF1 is critical for regulating the BRAF\/MEK\/ERK pathway in non-small cell lung carcinogenesis","volume":"78","author":"Wang","year":"2018","journal-title":"Cancer Res."},{"key":"10.1016\/j.yexcr.2026.115154_bib75","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.canlet.2022.01.030","article-title":"Inhibition of DCLK1 sensitizes resistant lung adenocarcinomas to EGFR-TKI through suppression of Wnt\/\u03b2-Catenin activity and cancer stemness","volume":"531","author":"Yan","year":"2022","journal-title":"Cancer Lett."},{"issue":"30","key":"10.1016\/j.yexcr.2026.115154_bib76","article-title":"Reversing MET-mediated resistance in oncogene-driven NSCLC by MET-activated wnt condensative prodrug","volume":"11","author":"Liu","year":"2024","journal-title":"Adv. Sci. (Weinh.)"},{"issue":"1","key":"10.1016\/j.yexcr.2026.115154_bib77","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/djt356","article-title":"Wnt signaling pathway in non-small cell lung cancer","volume":"106","author":"Stewart","year":"2014","journal-title":"J. Natl. Cancer Inst."},{"issue":"1","key":"10.1016\/j.yexcr.2026.115154_bib78","doi-asserted-by":"crossref","first-page":"4184","DOI":"10.1038\/s41467-019-12143-3","article-title":"USP7 inhibits Wnt\/\u03b2-catenin signaling through promoting stabilization of Axin","volume":"10","author":"Ji","year":"2019","journal-title":"Nat. Commun."},{"issue":"3","key":"10.1016\/j.yexcr.2026.115154_bib79","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbamcr.2025.119908","article-title":"The key vulnerabilities and therapeutic opportunities in the USP7-p53\/MDM2 axis in cancer","volume":"1872","author":"Saha","year":"2025","journal-title":"Biochim. Biophys. Acta Mol. Cell Res."},{"issue":"1","key":"10.1016\/j.yexcr.2026.115154_bib80","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1186\/s12931-022-01988-w","article-title":"miR-489-3p promotes malignant progression of non-small cell lung cancer through the inactivation of Wnt\/\u03b2-catenin signaling pathway via regulating USP48","volume":"23","author":"Zhang","year":"2022","journal-title":"Respir. Res."},{"key":"10.1016\/j.yexcr.2026.115154_bib81","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1630311","article-title":"KCTD10 inhibits lung cancer metastasis and angiogenesis via ubiquitin-mediated \u03b2-catenin degradation","volume":"16","author":"Yin","year":"2025","journal-title":"Front. Immunol."},{"issue":"9","key":"10.1016\/j.yexcr.2026.115154_bib82","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2024.114667","article-title":"The TRIM4 E3 ubiquitin ligase degrades TPL2 and is modulated by oncogenic KRAS","volume":"43","author":"Bansod","year":"2024","journal-title":"Cell Rep."},{"issue":"Pt 3","key":"10.1016\/j.yexcr.2026.115154_bib83","article-title":"The structural, functional, and regulatory insight of deubiquitinating enzyme - USP22","volume":"318","author":"Devi","year":"2025","journal-title":"Int. J. Biol. Macromol."},{"issue":"31","key":"10.1016\/j.yexcr.2026.115154_bib84","doi-asserted-by":"crossref","first-page":"2260","DOI":"10.1111\/1759-7714.15439","article-title":"USP22 promotes gefitinib resistance and inhibits ferroptosis in non-small cell lung cancer by deubiquitination of MDM2","volume":"15","author":"Lu","year":"2024","journal-title":"Thorac. Cancer"},{"key":"10.1016\/j.yexcr.2026.115154_bib85","article-title":"USP38: an important regulatory factor in tumor malignant progression","volume":"16","author":"Li","year":"2025","journal-title":"Front. Immunol."},{"issue":"5","key":"10.1016\/j.yexcr.2026.115154_bib86","doi-asserted-by":"crossref","first-page":"421","DOI":"10.3892\/ol.2021.12682","article-title":"USP18-deficiency in cervical carcinoma is crucial for the malignant behavior of tumor cells in an ERK signal-dependent manner","volume":"21","author":"Pan","year":"2021","journal-title":"Oncol. Lett."},{"key":"10.1016\/j.yexcr.2026.115154_bib87","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1038\/s41421-020-00188-4","article-title":"USP7 negatively controls global DNA methylation by attenuating ubiquitinated histone-dependent DNMT1 recruitment","volume":"6","author":"Li","year":"2020","journal-title":"Cell Discov."},{"issue":"9","key":"10.1016\/j.yexcr.2026.115154_bib88","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1038\/s41419-024-06796-2","article-title":"L3MBTL1, a polycomb protein, promotes Osimertinib acquired resistance through epigenetic regulation of DNA damage response in lung adenocarcinoma","volume":"15","author":"Zhang","year":"2024","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.yexcr.2026.115154_bib89","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.canlet.2019.02.015","article-title":"USP39 regulates DNA damage response and chemo-radiation resistance by deubiquitinating and stabilizing CHK2","volume":"449","author":"Wu","year":"2019","journal-title":"Cancer Lett."},{"issue":"16","key":"10.1016\/j.yexcr.2026.115154_bib90","doi-asserted-by":"crossref","first-page":"4811","DOI":"10.1111\/febs.16077","article-title":"Mechanism, specificity, and function of FANCD2-FANCI ubiquitination and deubiquitination","volume":"289","author":"Lemonidis","year":"2022","journal-title":"FEBS J."},{"issue":"7","key":"10.1016\/j.yexcr.2026.115154_bib91","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/S1673-8527(07)60065-4","article-title":"Fanconi anemia and ubiquitination","volume":"34","author":"Zhang","year":"2007","journal-title":"J. Genet. Genomics"},{"issue":"12","key":"10.1016\/j.yexcr.2026.115154_bib92","doi-asserted-by":"crossref","first-page":"2462","DOI":"10.1128\/MCB.05058-11","article-title":"The USP1\/UAF1 complex promotes double-strand break repair through homologous recombination","volume":"31","author":"Murai","year":"2011","journal-title":"Mol. Cell Biol."},{"issue":"4","key":"10.1016\/j.yexcr.2026.115154_bib93","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1038\/s41401-022-01003-4","article-title":"SNS-023 sensitizes hepatocellular carcinoma to sorafenib by inducing degradation of cancer drivers SIX1 and RPS16","volume":"44","author":"Liu","year":"2023","journal-title":"Acta Pharmacol. Sin."},{"issue":"4","key":"10.1016\/j.yexcr.2026.115154_bib94","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/j.molcel.2011.03.027","article-title":"Deubiquitinase USP37 is activated by CDK2 to antagonize APC(CDH1) and promote S phase entry","volume":"42","author":"Huang","year":"2011","journal-title":"Mol. Cell"},{"issue":"22","key":"10.1016\/j.yexcr.2026.115154_bib95","doi-asserted-by":"crossref","first-page":"2363","DOI":"10.2174\/0929867323666160510122624","article-title":"Skp2 inhibitors: novel anticancer strategies","volume":"23","author":"Lee","year":"2016","journal-title":"Curr. Med. Chem."},{"issue":"3","key":"10.1016\/j.yexcr.2026.115154_bib96","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1007\/s11030-022-10499-1","article-title":"Validation of catalytic site residues of Ubiquitin Specific Protease 2 (USP2) by molecular dynamic simulation and novel kinetics assay for rational drug design","volume":"27","author":"Ullah","year":"2023","journal-title":"Mol. Divers."},{"issue":"10","key":"10.1016\/j.yexcr.2026.115154_bib97","doi-asserted-by":"crossref","first-page":"3995","DOI":"10.21037\/tlcr-21-767","article-title":"Deubiquitinase USP5 promotes non-small cell lung cancer cell proliferation by stabilizing cyclin D1","volume":"10","author":"Zhang","year":"2021","journal-title":"Transl. Lung Cancer Res."},{"issue":"10","key":"10.1016\/j.yexcr.2026.115154_bib98","doi-asserted-by":"crossref","DOI":"10.1042\/BSR20210486","article-title":"USP52 inhibits cell proliferation by stabilizing PTEN protein in non-small cell lung cancer","volume":"41","author":"Zhu","year":"2021","journal-title":"Biosci. Rep."},{"issue":"12","key":"10.1016\/j.yexcr.2026.115154_bib99","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1111\/jvh.13886","article-title":"CHB patients with rtA181T-mutated HBV infection are associated with higher risk hepatocellular carcinoma due to increases in mutation rates of tumour suppressor genes","volume":"30","author":"Ning","year":"2023","journal-title":"J. Viral Hepat."},{"key":"10.1016\/j.yexcr.2026.115154_bib100","doi-asserted-by":"crossref","DOI":"10.1155\/2021\/3621828","article-title":"Prognostic value of BIM deletion in EGFR-mutant NSCLC patients treated with EGFR-TKIs: a meta-analysis","volume":"2021","author":"Lv","year":"2021","journal-title":"Biomed Res. Int."},{"issue":"5","key":"10.1016\/j.yexcr.2026.115154_bib101","doi-asserted-by":"crossref","first-page":"724","DOI":"10.15252\/embr.201541392","article-title":"The deubiquitinase Usp27x stabilizes the BH3-only protein Bim and enhances apoptosis","volume":"17","author":"Weber","year":"2016","journal-title":"EMBO Rep."},{"issue":"13","key":"10.1016\/j.yexcr.2026.115154_bib102","doi-asserted-by":"crossref","first-page":"3527","DOI":"10.1158\/0008-5472.CAN-16-3470","article-title":"Targeting FBW7 as a strategy to overcome resistance to targeted therapy in non-small cell lung cancer","volume":"77","author":"Ye","year":"2017","journal-title":"Cancer Res."},{"issue":"7","key":"10.1016\/j.yexcr.2026.115154_bib103","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1016\/j.cell.2005.06.009","article-title":"Mule\/ARF-BP1, a BH3-only E3 ubiquitin ligase, catalyzes the polyubiquitination of Mcl-1 and regulates apoptosis","volume":"121","author":"Zhong","year":"2005","journal-title":"Cell"},{"issue":"4","key":"10.1016\/j.yexcr.2026.115154_bib104","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1172\/JCI97325","article-title":"The deubiquitinase USP9X regulates FBW7 stability and suppresses colorectal cancer","volume":"128","author":"Khan","year":"2018","journal-title":"J. Clin. Investig."},{"issue":"3","key":"10.1016\/j.yexcr.2026.115154_bib105","first-page":"1657","article-title":"FBW7 in hematological tumors","volume":"19","author":"Zhu","year":"2020","journal-title":"Oncol. Lett."},{"issue":"1","key":"10.1016\/j.yexcr.2026.115154_bib106","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1080\/15384047.2020.1856756","article-title":"Epigenetic modulation of FBW7\/Mcl-1 pathway for lung cancer therapy","volume":"22","author":"Kim","year":"2021","journal-title":"Cancer Biol. Ther."},{"issue":"1","key":"10.1016\/j.yexcr.2026.115154_bib107","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1186\/s13046-024-03220-7","article-title":"MDM2 drives resistance to Osimertinib by contextually disrupting FBW7-mediated destruction of MCL-1 protein in EGFR mutant NSCLC","volume":"43","author":"Liu","year":"2024","journal-title":"J. Exp. Clin. Cancer Res."},{"issue":"Pt 1","key":"10.1016\/j.yexcr.2026.115154_bib108","article-title":"A novel GSH depletor for simultaneous ferroptosis and cuproptosis activation in hepatocellular carcinoma","volume":"243","author":"Yang","year":"2026","journal-title":"Biochem. Pharmacol."},{"issue":"6","key":"10.1016\/j.yexcr.2026.115154_bib109","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1111\/cas.12145","article-title":"FBXO15 regulates P-glycoprotein\/ABCB1 expression through the ubiquitin--proteasome pathway in cancer cells","volume":"104","author":"Katayama","year":"2013","journal-title":"Cancer Sci."},{"key":"10.1016\/j.yexcr.2026.115154_bib110","doi-asserted-by":"crossref","DOI":"10.1038\/srep36134","article-title":"RSK1 protects P-glycoprotein\/ABCB1 against ubiquitin-proteasomal degradation by downregulating the ubiquitin-conjugating enzyme E2 R1","volume":"6","author":"Katayama","year":"2016","journal-title":"Sci. Rep."},{"issue":"9","key":"10.1016\/j.yexcr.2026.115154_bib111","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines9091143","article-title":"Rutaecarpine increases anticancer drug sensitivity in drug-resistant cells through MARCH8-Dependent ABCB1 degradation","volume":"9","author":"Zou","year":"2021","journal-title":"Biomedicines"},{"issue":"2","key":"10.1016\/j.yexcr.2026.115154_bib112","doi-asserted-by":"crossref","DOI":"10.3390\/ijms25020807","article-title":"Natural product-based glycolysis inhibitors as a therapeutic strategy for epidermal growth factor receptor-tyrosine kinase inhibitor-resistant non-small cell lung cancer","volume":"25","author":"Park","year":"2024","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.yexcr.2026.115154_bib113","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1186\/s12943-020-01262-x","article-title":"The role of ubiquitination and deubiquitination in cancer metabolism","volume":"19","author":"Sun","year":"2020","journal-title":"Mol. Cancer"},{"issue":"23","key":"10.1016\/j.yexcr.2026.115154_bib114","doi-asserted-by":"crossref","DOI":"10.1016\/j.devcel.2025.07.014","article-title":"Dapk2 dysfunction leads to Mic60 lactylation and mitochondrial metabolic reprogramming, promoting lung cancer EGFR-TKI resistance and metastasis","volume":"60","author":"Zheng","year":"2025","journal-title":"Dev. Cell"},{"issue":"18","key":"10.1016\/j.yexcr.2026.115154_bib115","doi-asserted-by":"crossref","first-page":"5906","DOI":"10.1074\/jbc.RA119.011869","article-title":"The cytochrome P450 enzyme CYP24A1 increases proliferation of mutant KRAS-dependent lung adenocarcinoma independent of its catalytic activity","volume":"295","author":"Huang","year":"2020","journal-title":"J. Biol. Chem."},{"issue":"6","key":"10.1016\/j.yexcr.2026.115154_bib116","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1038\/s41401-018-0187-3","article-title":"THZ1 suppresses human non-small-cell lung cancer cells in vitro through interference with cancer metabolism","volume":"40","author":"Cheng","year":"2019","journal-title":"Acta Pharmacol. Sin."},{"issue":"1","key":"10.1016\/j.yexcr.2026.115154_bib117","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1158\/1535-7163.MCT-06-0255","article-title":"Epidermal growth factor receptor inhibition sensitizes renal cell carcinoma cells to the cytotoxic effects of bortezomib","volume":"6","author":"An","year":"2007","journal-title":"Mol. Cancer Therapeut."},{"issue":"3","key":"10.1016\/j.yexcr.2026.115154_bib118","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1002\/jcp.21444","article-title":"Synergistic anti-proliferative and pro-apoptotic activity of combined therapy with bortezomib, a proteasome inhibitor, with anti-epidermal growth factor receptor (EGFR) drugs in human cancer cells","volume":"216","author":"Cascone","year":"2008","journal-title":"J. Cell. Physiol."},{"issue":"8","key":"10.1016\/j.yexcr.2026.115154_bib119","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1097\/JTO.0b013e3180f60bb3","article-title":"Schedule-dependent interaction between the proteosome inhibitor bortezomib and the EGFR-TK inhibitor erlotinib in human non-small cell lung cancer cell lines","volume":"2","author":"Piperdi","year":"2007","journal-title":"J. Thorac. Oncol."},{"issue":"25","key":"10.1016\/j.yexcr.2026.115154_bib120","doi-asserted-by":"crossref","first-page":"6107","DOI":"10.1200\/JCO.2005.01.136","article-title":"Proteasome inhibition with bortezomib (PS-341): a phase I study with pharmacodynamic end points using a day 1 and day 4 schedule in a 14-day cycle","volume":"23","author":"Hamilton","year":"2005","journal-title":"J. Clin. Oncol."},{"issue":"12","key":"10.1016\/j.yexcr.2026.115154_bib121","doi-asserted-by":"crossref","DOI":"10.1242\/dmm.049358","article-title":"Bortezomib-induced neurotoxicity in human neurons is the consequence of nicotinamide adenine dinucleotide depletion","volume":"15","author":"Snavely","year":"2022","journal-title":"Dis. Model. Mech."},{"issue":"16","key":"10.1016\/j.yexcr.2026.115154_bib122","doi-asserted-by":"crossref","first-page":"5120","DOI":"10.1111\/bph.70501","article-title":"Shared and specific molecular mechanisms of proteasome inhibitors in chemotherapy-induced peripheral neurotoxicity","volume":"183","author":"Iseppon","year":"2026","journal-title":"Br. J. Pharmacol."},{"issue":"31","key":"10.1016\/j.yexcr.2026.115154_bib123","doi-asserted-by":"crossref","first-page":"5025","DOI":"10.1200\/JCO.2006.06.1853","article-title":"Randomized phase II study of bortezomib alone and bortezomib in combination with docetaxel in previously treated advanced non-small-cell lung cancer","volume":"24","author":"Fanucchi","year":"2006","journal-title":"J. Clin. Oncol."},{"issue":"5","key":"10.1016\/j.yexcr.2026.115154_bib124","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1158\/1078-0432.CCR-20-2853","article-title":"Proteasome inhibition overcomes ALK-TKI resistance in ALK-Rearranged\/TP53-Mutant NSCLC via noxa expression","volume":"27","author":"Tanimoto","year":"2021","journal-title":"Clin. Cancer Res."},{"issue":"4","key":"10.1016\/j.yexcr.2026.115154_bib125","article-title":"The role of proteasomes in tumorigenesis","volume":"11","author":"Zhou","year":"2024","journal-title":"Genes Dis."},{"issue":"1","key":"10.1016\/j.yexcr.2026.115154_bib126","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.lungcan.2009.05.009","article-title":"Phase II study of the proteasome inhibitor bortezomib (PS-341, Velcade) in chemotherapy-na\u00efve patients with advanced stage non-small cell lung cancer (NSCLC)","volume":"68","author":"Li","year":"2010","journal-title":"Lung Cancer"},{"issue":"8","key":"10.1016\/j.yexcr.2026.115154_bib127","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1097\/JTO.0b013e3181aba89f","article-title":"A randomized phase 2 study of erlotinib alone and in combination with bortezomib in previously treated advanced non-small cell lung cancer","volume":"4","author":"Lynch","year":"2009","journal-title":"J. Thorac. Oncol."},{"issue":"1","key":"10.1016\/j.yexcr.2026.115154_bib128","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1007\/s10637-013-9980-5","article-title":"Vorinostat and bortezomib as third-line therapy in patients with advanced non-small cell lung cancer: a Wisconsin Oncology Network Phase II study","volume":"32","author":"Hoang","year":"2014","journal-title":"Invest. N. Drugs"},{"issue":"16","key":"10.1016\/j.yexcr.2026.115154_bib129","doi-asserted-by":"crossref","first-page":"13666","DOI":"10.1021\/acs.jmedchem.4c00208","article-title":"Distinct amino acid-based PROTACs target oncogenic kinases for degradation in non-small cell lung cancer (NSCLC)","volume":"67","author":"Zhang","year":"2024","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.yexcr.2026.115154_bib130","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2023.102561","article-title":"Proteolysis targeting chimeras in non-small cell lung cancer","volume":"117","author":"Hagopian","year":"2023","journal-title":"Cancer Treat Rev."},{"key":"10.1016\/j.yexcr.2026.115154_bib131","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2025.1604661","article-title":"Targeted degradation of EGFR 19Del by PROTACs suppresses tumor growth in non-small-cell lung cancer","volume":"16","author":"Piao","year":"2025","journal-title":"Front. Pharmacol."},{"issue":"7","key":"10.1016\/j.yexcr.2026.115154_bib132","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1158\/1535-7163.MCT-21-0835","article-title":"HJM-561, a potent, selective, and orally bioavailable EGFR PROTAC that overcomes osimertinib-resistant EGFR triple mutations","volume":"21","author":"Du","year":"2022","journal-title":"Mol. Cancer Therapeut."},{"issue":"1","key":"10.1016\/j.yexcr.2026.115154_bib133","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.chembiol.2017.09.009","article-title":"The advantages of targeted protein degradation over inhibition: an RTK case study","volume":"25","author":"Burslem","year":"2018","journal-title":"Cell Chem. Biol."},{"key":"10.1016\/j.yexcr.2026.115154_bib134","doi-asserted-by":"crossref","DOI":"10.1016\/j.prp.2025.156001","article-title":"Exploiting E3 ligases for lung cancer therapy: the promise of DCAF-PROTACs","volume":"270","author":"Hussain","year":"2025","journal-title":"Pathol. Res. Pract."},{"issue":"6","key":"10.1016\/j.yexcr.2026.115154_bib135","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.2174\/0109298673382742250619055201","article-title":"Targeted protein degradation in lung cancer: the emerging role of PROTAC technology and E3 ligases","volume":"33","author":"Hussain","year":"2026","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.yexcr.2026.115154_bib136","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2024.107204","article-title":"Expansion of targeted degradation by Gilteritinib-Warheaded PROTACs to ALK fusion proteins","volume":"145","author":"Yokoo","year":"2024","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.yexcr.2026.115154_bib137","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2024.107590","article-title":"Discovery of a first-in-class protein degrader for the c-ros oncogene 1 (ROS1)","volume":"150","author":"Yang","year":"2024","journal-title":"Bioorg. Chem."},{"issue":"26","key":"10.1016\/j.yexcr.2026.115154_bib138","article-title":"Antitumor effect of Anti-c-Myc aptamer-based PROTAC for degradation of the c-Myc protein","volume":"11","author":"Wang","year":"2024","journal-title":"Adv. Sci. (Weinh.)"},{"key":"10.1016\/j.yexcr.2026.115154_bib139","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2025.118485","article-title":"Direct small-molecule inhibitors of the Keap1-Nrf2 protein-protein interaction: scaffold evolution, PROTAC strategies, and therapeutic implications","volume":"303","author":"Cho","year":"2026","journal-title":"Eur. J. Med. Chem."},{"issue":"1","key":"10.1016\/j.yexcr.2026.115154_bib140","doi-asserted-by":"crossref","DOI":"10.1016\/j.omtn.2024.102137","article-title":"Oligo-PROTAC strategy for cell-selective and targeted degradation of activated STAT3","volume":"35","author":"Hall","year":"2024","journal-title":"Mol. Ther. Nucleic Acids"},{"issue":"1","key":"10.1016\/j.yexcr.2026.115154_bib141","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1186\/s43556-022-00112-0","article-title":"An overview of PROTACs: a promising drug discovery paradigm","volume":"3","author":"Liu","year":"2022","journal-title":"Mol Biomed"},{"issue":"1","key":"10.1016\/j.yexcr.2026.115154_bib142","doi-asserted-by":"crossref","first-page":"103","DOI":"10.7150\/thno.99588","article-title":"Development of dual aptamers-functionalized c-MET PROTAC degraders for targeted therapy of osteosarcoma","volume":"15","author":"Fu","year":"2025","journal-title":"Theranostics"},{"issue":"6","key":"10.1016\/j.yexcr.2026.115154_bib143","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1021\/acsmedchemlett.3c00181","article-title":"Potent and selective BCL-XL inhibitors and PROTAC compounds as potential cancer treatment and immunotherapy","volume":"14","author":"Kargbo","year":"2023","journal-title":"ACS Med. Chem. Lett."},{"issue":"12","key":"10.1016\/j.yexcr.2026.115154_bib144","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics14122829","article-title":"Design, synthesis and in vitro investigation of cabozantinib-based PROTACs to target c-Met kinase","volume":"14","author":"Sachkova","year":"2022","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.yexcr.2026.115154_bib145","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2026.115927","article-title":"Enabling formulations for PROTACs: a line-of-sight to clinic","author":"Swedrowska","year":"2026","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"1","key":"10.1016\/j.yexcr.2026.115154_bib146","doi-asserted-by":"crossref","DOI":"10.1080\/14756366.2026.2700038","article-title":"Evolving CRBN ligands enhance the drug-like properties of protein degraders","volume":"41","author":"Ji","year":"2026","journal-title":"J Enzyme Inhib Med Chem"},{"key":"10.1016\/j.yexcr.2026.115154_bib147","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1146\/annurev-pharmtox-022123-104147","article-title":"From thalidomide to rational molecular glue design for targeted protein degradation","volume":"64","author":"Oleinikovas","year":"2024","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"issue":"8","key":"10.1016\/j.yexcr.2026.115154_bib148","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1038\/s41388-024-03241-8","article-title":"Discovery of a molecular glue for EGFR degradation","volume":"44","author":"Wang","year":"2025","journal-title":"Oncogene"},{"issue":"4","key":"10.1016\/j.yexcr.2026.115154_bib149","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1002\/ijc.31726","article-title":"GPRC5A deficiency leads to dysregulated MDM2 via activated EGFR signaling for lung tumor development","volume":"144","author":"Song","year":"2019","journal-title":"Int. J. Cancer"},{"issue":"2","key":"10.1016\/j.yexcr.2026.115154_bib150","doi-asserted-by":"crossref","first-page":"110","DOI":"10.2174\/156800908783769373","article-title":"Targeting IAP (inhibitor of apoptosis) proteins for therapeutic intervention in tumors","volume":"8","author":"Vucic","year":"2008","journal-title":"Curr. Cancer Drug Targets"},{"issue":"11","key":"10.1016\/j.yexcr.2026.115154_bib151","doi-asserted-by":"crossref","first-page":"2596","DOI":"10.1002\/ijc.30649","article-title":"Induction of Cbl-dependent epidermal growth factor receptor degradation in Ling Zhi-8 suppressed lung cancer","volume":"140","author":"Lin","year":"2017","journal-title":"Int. J. Cancer"},{"issue":"1","key":"10.1016\/j.yexcr.2026.115154_bib152","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.canlet.2014.12.043","article-title":"Chimeric ubiquitin ligases inhibit non-small cell lung cancer via negative modulation of EGFR signaling","volume":"359","author":"Zhong","year":"2015","journal-title":"Cancer Lett."},{"issue":"2","key":"10.1016\/j.yexcr.2026.115154_bib153","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1172\/JCI70297","article-title":"Inactivation of SAG\/RBX2 E3 ubiquitin ligase suppresses KrasG12D-driven lung tumorigenesis","volume":"124","author":"Li","year":"2014","journal-title":"J. Clin. Investig."},{"issue":"12","key":"10.1016\/j.yexcr.2026.115154_bib154","doi-asserted-by":"crossref","DOI":"10.1002\/mco2.70517","article-title":"KSQ-4279, an inhibitor of ubiquitin specific peptidase 1, enhanced the chemotherapeutic efficacy in ABCB1\/ABCG2\/ABCC1-Mediated multidrug resistant cancers","volume":"6","author":"Yang","year":"2025","journal-title":"MedComm"},{"issue":"5","key":"10.1016\/j.yexcr.2026.115154_bib155","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1007\/s13402-022-00699-0","article-title":"Proteasomal deubiquitylase activity enhances cell surface recycling of the epidermal growth factor receptor in non-small cell lung cancer","volume":"45","author":"Wang","year":"2022","journal-title":"Cell. Oncol."},{"issue":"1","key":"10.1016\/j.yexcr.2026.115154_bib156","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1038\/s41598-024-84217-2","article-title":"Orthogonal validation of PROTAC mediated degradation of the integral membrane proteins EGFR and c-MET","volume":"15","author":"Ruffilli","year":"2025","journal-title":"Sci. Rep."},{"issue":"20","key":"10.1016\/j.yexcr.2026.115154_bib157","doi-asserted-by":"crossref","first-page":"13645","DOI":"10.1021\/acs.jmedchem.2c00408","article-title":"Discovery of potent OTUB1\/USP8 dual inhibitors targeting proteostasis in non-small-cell lung cancer","volume":"65","author":"Tan","year":"2022","journal-title":"J. Med. Chem."},{"issue":"31","key":"10.1016\/j.yexcr.2026.115154_bib158","doi-asserted-by":"crossref","first-page":"5025","DOI":"10.1200\/JCO.2006.06.1853","article-title":"Randomized phase II study of bortezomib alone and bortezomib in combination with docetaxel in previously treated advanced non-small-cell lung cancer","volume":"24","author":"Fanucchi","year":"2006","journal-title":"J. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.yexcr.2026.115154_bib159","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/j.lungcan.2009.07.011","article-title":"A randomized phase II study of bortezomib and pemetrexed, in combination or alone, in patients with previously treated advanced non-small-cell lung cancer","volume":"68","author":"Scagliotti","year":"2010","journal-title":"Lung Cancer"},{"issue":"2","key":"10.1016\/j.yexcr.2026.115154_bib160","doi-asserted-by":"crossref","DOI":"10.1101\/mcs.a003665","article-title":"Exceptional responders with invasive mucinous adenocarcinomas: a phase 2 trial of bortezomib in patients with KRAS G12D-mutant lung cancers","volume":"5","author":"Drilon","year":"2019","journal-title":"Cold Spring Harb. Mol. Case Stud."},{"issue":"1","key":"10.1016\/j.yexcr.2026.115154_bib161","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.lungcan.2009.05.009","article-title":"Phase II study of the proteasome inhibitor bortezomib (PS-341, Velcade) in chemotherapy-na\u00efve patients with advanced stage non-small cell lung cancer (NSCLC)","volume":"68","author":"Li","year":"2010","journal-title":"Lung Cancer"},{"issue":"6","key":"10.1016\/j.yexcr.2026.115154_bib162","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1097\/JTO.0b013e31824de2fa","article-title":"Phase-I\/II study of bortezomib in combination with carboplatin and bevacizumab as first-line therapy in patients with advanced non-small-cell lung cancer","volume":"7","author":"Piperdi","year":"2012","journal-title":"J. Thorac. Oncol."},{"issue":"1","key":"10.1016\/j.yexcr.2026.115154_bib163","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1097\/JTO.0b013e3181915052","article-title":"Bortezomib plus gemcitabine\/carboplatin as first-line treatment of advanced non-small cell lung cancer: a phase II Southwest Oncology Group Study (S0339)","volume":"4","author":"Davies","year":"2009","journal-title":"J. Thorac. Oncol."},{"issue":"8","key":"10.1016\/j.yexcr.2026.115154_bib164","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1097\/JTO.0b013e3181aba89f","article-title":"A randomized phase 2 study of erlotinib alone and in combination with bortezomib in previously treated advanced non-small cell lung cancer","volume":"4","author":"Lynch","year":"2009","journal-title":"J. Thorac. Oncol."},{"issue":"3","key":"10.1016\/j.yexcr.2026.115154_bib165","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1007\/s10637-015-0230-x","article-title":"Phase 1 study of ixazomib, an investigational proteasome inhibitor, in advanced non-hematologic malignancies","volume":"33","author":"Smith","year":"2015","journal-title":"Invest. N. Drugs"},{"issue":"6","key":"10.1016\/j.yexcr.2026.115154_bib166","doi-asserted-by":"crossref","first-page":"2303","DOI":"10.1007\/s10637-011-9766-6","article-title":"Phase 1 clinical trial of the novel proteasome inhibitor marizomib with the histone deacetylase inhibitor vorinostat in patients with melanoma, pancreatic and lung cancer based on in vitro assessments of the combination","volume":"30","author":"Millward","year":"2012","journal-title":"Invest. N. Drugs"},{"issue":"2","key":"10.1016\/j.yexcr.2026.115154_bib167","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.cllc.2023.10.011","article-title":"A phase II trial of pevonedistat and docetaxel in patients with previously treated advanced non-small-cell lung cancer","volume":"25","author":"Qin","year":"2024","journal-title":"Clin. Lung Cancer"},{"key":"10.1016\/j.yexcr.2026.115154_bib168","doi-asserted-by":"crossref","DOI":"10.1177\/17588359251332154","article-title":"Xevinapant plus avelumab in advanced solid tumours, with a dose expansion in advanced non-small-cell lung cancer: exploratory biomarker, safety and efficacy analyses from an open-label, nonrandomised phase Ib study","volume":"17","author":"Goss","year":"2025","journal-title":"Ther. Adv. Med. Oncol."}],"container-title":["Experimental Cell Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014482726002715?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014482726002715?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T20:33:46Z","timestamp":1790714026000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0014482726002715"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":168,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["S0014482726002715"],"URL":"https:\/\/doi.org\/10.1016\/j.yexcr.2026.115154","relation":{},"ISSN":["0014-4827"],"issn-type":[{"value":"0014-4827","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Targeting the ubiquitin-proteasome system: An emerging paradigm for overcoming resistance to targeted therapy in non-small cell lung cancer","name":"articletitle","label":"Article Title"},{"value":"Experimental Cell Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.yexcr.2026.115154","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"115154"}}